Table 2.

Arteriolar perfusion in LZR and OZR

	LZR	OZR	O-P	O-T	O-SQ	O-LN	O-PT	O-PSQ	O-PLN	O-TLN	O-TSQ	O-PTSQ
1A
ID	94 ± 4	85 ± 6	92 ± 3	87 ± 6	88 ± 5	84 ± 6	93 ± 3	93 ± 4	90 ± 4	86 ± 3	86 ± 4	93 ± 3
VRBC	56 ± 5	46 ± 6	48 ± 5	45 ± 6	49 ± 7	38 ± 6*	52 ± 6	53 ± 5	46 ± 5	48 ± 5	48 ± 4	53 ± 5
Q	245 ± 14	165 ± 20*	200 ± 15	169 ± 14*	186 ± 9*	134 ± 15*	219 ± 6†	224 ± 14†	183 ± 13*	175 ± 13*	176 ± 14*	227 ± 17†
2A
ID	75 ± 4	66 ± 5	72 ± 3	69 ± 6	68 ± 6	64 ± 5	73 ± 4	74 ± 4	71 ± 5	67 ± 6	69 ± 5	74 ± 4
VRBC	40 ± 6	35 ± 5	40 ± 5	36 ± 6	36 ± 5	32 ± 4	39 ± 5	39 ± 4	36 ± 6	37 ± 5	38 ± 6	40 ± 4
Q	112 ± 10	74 ± 12*	100 ± 9	84 ± 9*	82 ± 5*	65 ± 6*	102 ± 5	105 ± 8	89 ± 9	82 ± 11*	89 ± 12	108 ± 6†
3A
ID	53 ± 4	48 ± 7	50 ± 5	53 ± 6	53 ± 5	47 ± 6	52 ± 5	53 ± 5	48 ± 5	52 ± 5	53 ± 6	53 ± 5
VRBC	20 ± 4	14 ± 3	17 ± 4	14 ± 3	14 ± 3	12 ± 3	18 ± 3	18 ± 4	15 ± 4	12 ± 3	14 ± 4	20 ± 2
Q	28 ± 4	16 ± 4*	21 ± 3	19 ± 4	19 ± 3	13 ± 3*	24 ± 5	25 ± 5	17 ± 3	16 ± 3	19 ± 4	28 ± 4*
4A
ID	36 ± 4	30 ± 3	31 ± 3	33 ± 5	32 ± 4	28 ± 3	34 ± 5	34 ± 4	29 ± 4	32 ± 5	35 ± 4	35 ± 3
VRBC	12 ± 3	8 ± 2	12 ± 3	9 ± 2	10 ± 3	8 ± 2	11 ± 2	12 ± 2	8 ± 2	9 ± 2	9 ± 2	12 ± 2
Q	7.8 ± 1.9	3.7 ± 1.5	5.5 ± 1.7	4.7 ± 1.1	4.8 ± 1.3	3.1 ± 0.8*	6.1 ± 1.6	6.6 ± 1.3	3.5 ± 0.9	4.3 ± 1.2	5.5 ± 1.4	7.2 ± 1.6
5A
ID	21 ± 3	18 ± 3	18 ± 2	20 ± 3	19 ± 3	18 ± 3	19 ± 2	20 ± 3	18 ± 2	19 ± 3	19 ± 2	20 ± 2
VRBC	7 ± 1	4 ± 1	5 ± 2	4 ± 1	4 ± 1	3 ± 1	6 ± 2	7 ± 2	5 ± 2	5 ± 2	5 ± 1	7 ± 1
Q	1.5 ± 0.3	0.7 ± 0.2*	0.8 ± 0.2	0.8 ± 0.2	0.7 ± 0.2*	0.5 ± 0.2*	1.1 ± 0.3	1.3 ± 0.2	0.8 ± 0.2	0.8 ± 0.2	0.8 ± 0.3	1.4 ± 0.3

Data are presented as means ± SE. Data are presented for arteriolar inner diameter (ID; μm), centerline erythrocyte velocity (V_RBC; mm/s), and volume perfusion within the arteriole (Q; nl/s).

^*P < 0.05 vs. LZR;

^†P < 0.05 vs. OZR. P denotes treatment with phentolamine; T denotes treatment with TEMPOL; SQ denotes treatment with SQ-29548; LN denotes treatment with l-NAME; with combinations representing treatment with multiple agents.